BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33815356)

  • 1. Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.
    Zhang L; Zhang B; Dou Z; Wu J; Iranmanesh Y; Jiang B; Sun C; Zhang J
    Front Immunol; 2021; 12():582594. PubMed ID: 33815356
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
    Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
    Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
    Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
    Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
    Hwang K; Koh EJ; Choi EJ; Kang TH; Han JH; Choe G; Park SH; Yearley JH; Annamalai L; Blumenschein W; Sathe M; McClanahan T; Jung H; Wang KC; Kim SK; Kim CY
    J Neurooncol; 2018 Sep; 139(2):281-291. PubMed ID: 29730815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.
    Müller S; Agnihotri S; Shoger KE; Myers MI; Smith N; Chaparala S; Villanueva CR; Chattopadhyay A; Lee AV; Butterfield LH; Diaz A; Okada H; Pollack IF; Kohanbash G
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
    Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
    J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
    Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
    Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
    Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
    Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 17. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
    Kim AK; Gani F; Layman AJ; Besharati S; Zhu Q; Succaria F; Engle EL; Bhaijee F; Goggins MB; Llosa NJ; Pawlik TM; Yarchoan M; Jaffee EM; Simons HC; Taube JM; Anders RA
    Cancer Immunol Res; 2019 May; 7(5):805-812. PubMed ID: 30902819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.